Long term treatment of myeloproliferative disease with interferon-α- 2b: Feasibility and efficacy

Cancer

Volumn 83, Issue 6, 1998, Pages 1205-1213

  Gilbert, Harriet S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Interferon; Long term efficacy; Myeloproliferative disease; Therapy

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE DISORDER; PHLEBOTOMY; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTHEMIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; HUMANS; INTERFERON ALFA-2A; MIDDLE AGED; MYELOID METAPLASIA; PLATELET COUNT; POLYCYTHEMIA VERA; REMISSION INDUCTION; SPLEEN; THROMBOCYTOSIS;

EID: 0032530861     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8     Document Type: Article

References (54)

1. Gilbert HS. Myeloproliferative disorders. Clin Geriatr Med 1985;1:773-93.
2. Gilbert HS. Polycythemia vera and other polycythemic conditions. In: Rakel RE, editor. Conn's current therapy. Philadelphia: W.B. Saunders, 1989:379-84.
3. Gilbert HS. Diagnosis and treatment of polycythemia vera, agnogenic myeloid metaplasia, and essential thrombocythemia. In: Wiernik P, Canellos GP, Kyle RA, Schiffer CA, editors. Neoplastic diseases of the blood. New York: Churchill Livingstone, 1991:123-36.
4. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet, and monocyte-macrophage. Am J Med 1977;63:125-30.
5. Van Slyck EJ, Weiss L, Dully M. Chromosomal evidence for the secondary role of fibroblastic proliferation in acute myelofibrosis. Blood 1970;36:729-35.
6. Greenberg BR, Wilson FD, Woo L, Jenks HM. Cytogenetics of fibroblast colonies in Ph1-positive chronic myelogenous leukemia. Blood 1978;51:1039-44.
7. Castro-Malaspina H, Rabellino EM, Yen A, Nachman RL, Moore MA. Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood 1981;57:781-7.
8. Ross R, Vogel A. The platelet derived growth factor. Cell 1978;14:203-10.
9. Burstein SA, Malpass TW, Yee E, Kadin M, Brigden M, Adamson JW, et al. Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis. Br J Haematol 1984;57:383-92.
10. Truong LD, Saleem A, Schwartz MR. Acute myelofibrosis: a report of four cases and review of the literature. Medicine (Baltimore) 1984;63:182-7.
11. Blume KG, Beutler E, Brass KJ, Chillar RK, Ellington OB, Fahey JL, et al. Bone marrow ablation and allogeneic marrow transplantation in acute leukemia. N Engl J Med 1980; 302:1041-6.
12. Rappeport J, Parkman R, Belli J, Levey R, Rosen F, Nathan D. Reversibility of myelofibrosis after bone marrow transplantation [abstract]. Blood 1978;52:271.
13. Wolf JL, Spruce WE, Bearman RM, Forman SJ, Scott EP, Fahey JL, et al. Reversal of acute (malignant) myelosclerosis by allogeneic bone marrow transplantation. Blood 1982;59: 191-3.
14. Adamson JW, Hollinger FB, Snyder EL, Bianco C. Challenges to transfusion medicine: infectious and immunologic complications of blood transfusions. In: Kaushansky K, McArthur JR, editors. Hematology - 1995. Seattle: Smith, Bucklin, and Associates, 1995:82-92.
15. Foon KA, Maluish AE, Abrams PG, Wrightington S, Stevenson HC, Alarif A, et al. Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic results. Am J Med 1986;80:351-6.
16. Golomb HM, Fefer A, Golde DW, Ozer H, Portlock C, Silber R, et al. Update of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon alfa-2b. Semin Oncol 1988;15(Suppl 5):7-9.
17. Talpaz M, Mavligit G, Keating M, Walters RS, Gutterman JU. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med 1983;99: 789-92.
18. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU, et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986;314:1065-9.
19. Velu T, Delwiche F, Flament J, Monsieur R, Stryckmans P, Wybram J. Therapy of essential thrombocythemia with human alpha 2 recombinant interferon [abstract]. Blood 1984; 64(Suppl 1):176.
20. Silver RT. A new treatment for polycythemia vera: recombinant Interferon (rIFN) alfa-2b [abstract]. Blood 1988;72:227a.
21. Gilbert HS. Remission of myeloid metaplasia induced by recombinant alpha interferon [abstract]. AAP Hematol Clin Res 1988;36:613a.
22. Gilbert HS. Persistence of remission of myeloid metaplasia after treatment with recombinant interferon alpha-2b [ab-stract]. Blood 1988;72:200a.
23. Gilbert HS. Regression of myeloid metaplasia during IFN-α2b treatment of myeloproliferative disease is accompanied by reduction in circulating concentrations of colony-stimulating factor-1 [abstract], Clin Res 1989;37:545A.
24. Gilbert H. Long-term treatment of myeloproliferative disease (MPD) with interferon alfa-2b (IFN): feasibility and efficacy [abstract]. Proc Am Soc Clin Oncol 1995;14:429A.
25. Gilbert HS. The role of alfa interferon (IFN) in treating chronic myeloproliferative disease (MPD): indications and results of long-term management [abstract]. Blood 1995;86: 48A.
26. Pfeffer LM, Murphy J, Tamm I. Interferon effects on the growth and division of human fibroblasts. Exp Cell Res 1979; 121:111-20.
27. Jasny BR, Pfeffer LM, Tamm I. Effects of beta-interferon on human fibroblasts at different population doubling levels. Proliferation, cell volume, thymidine uptake, and DNA synthesis. J Exp Med 1984;159:1741-9.
28. Jimenez S, Freundlich B, Rosenbloom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 1984;74:112-6.
29. Dukes P, Iyadi P, Ortega J, Shore N, Gomperts E. Inhibitory effects of interferons on mouse megakaryocytic progenitor cells in culture. Exp Hematol 1980:8:1048-51.
30. Scott GM, Secher DS, Flowers D, Bate J, Cantell K, Tyrrell DA. Toxicity of interferon. BMJ 1981;282:1345-8.
31. Ingimarsson S, Cantell K, Stander H. Side effects of long term treatment with human leukocyte interferon. J Infect Dis 1979;140:560-3.
32. Mattson K, Niiranen A, Iivanainen M, Farkkila M, Bergstrom L, Holsti LR, et al. Neurotoxicity of interferon [letter]. Cancer Treat Rep 1982;67:958-61.
33. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986;23:132-43.
34. Giralt S, Kantarjian H, Talpaz M. Treatment of chronic myelogenous leukemia. Semin Oncol 1995;22:396-404.
35. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993;82:691-703.
36. Finelli C, Gugliotta L, Gamberi B, Vianelli N, Visani G, Tura S. Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa. Am J Hematol 1993;43:316-8.
37. Foa P, Massaro P, Ribera S, Iurlo A, Mezzanotte C, Giandalia D, et al. Role of interferon alpha-2a in the treatment of polycythemia vera. Am J Hematol 1995;48:55-7.
38. Tornebohm-Roche E, Merup M, Lockner D, Paul C. α-2a Interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis. Am J Hematol 1994;48:163-7.
39. Muller EW, de Wolf JT, Egger R, Wijermans PW, Huijgens PC, Halie MR, et al. Long-term treatment with interferon-α2b for severe pruritus in patients with polycythemia vera. Br J Haematol 1995;89:313-8.
40. Cimino R, Rametta V, Matera C, Mele G, Mettivier V, Ferrara F. Recombinant Interferon α-2b in the treatment of polycythemia vera. Am J Hematol 1993;44:155-7.
41. Silver RT. Interferon-α2b: a new treatment for polycythemia vera. Ann Intern Med 1993;119:1091-2.
42. Sacchi S, Leoni P, Liberati M, Riccardi A, Tabillo A, Tartoni P, et al. A prospective comparison between treatment with phlebotomy and with interferon-alpha in patients with polycythemia vera. Ann Hematol 1994;68:247-50.
43. Castello G, Lerza R, Cerruti A, Cavallini D, Bogliolo G, Pannacciulli I. The in vitro and in vivo effect of recombinant interferon α-2a on circulating haemopoietic progenitors in polycythemia vera. Br J Haematol 1994;87:621-3.
44. de Wolf JT, Hendriks DW, Egger RC, Esselink MT, Halie MR, Vellenga E. Alpha-interferon for intractable pruritus in polycythaemia vera [letter]. Lancet 1991;337:241.
45. Ariad S, Bezwoda WR. Alpha interferon for polycythemia vera [letter]. Blood 1991;77:670.
46. Kasparu H, Bernhart M, Krieger O, Lutz D. Remission may continue after termination of IFNα-2b treatment for essential thrombocythemia. Eur J Haematol 1992;48:33-6.
47. Sacchi S, Tabilio A, Leoni P, Riccardi A, Vecchi A, Messora C, et al. Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term α-IFN treatment. Ann Hematol 1993;66:245-6.
48. Middlehoff G, Boll I. A long-term clinical trial of interferon alpha-therapy in essential thrombocythemia. Ann Hematol 1992;64:207-9.
49. Lopes E, Ribeiro MM, Silva MJ, Gandra M, Principe F, Granato C. Essential thrombocythemia: clinical features, therapy and follow-up of 12 cases. Leukemia 1992;6(Suppl 3):138S-40S.
50. Dalla KP, Zeigler ZR, Shadduck RK. α-Interferon in myelofibrosis: a case report. Br J Haematol 1994;86:654-6.
51. Radin AI, Buckley P, Duffy TP. Interferon therapy for agnogenic metaplasia complicated by hemolytic anemia. Hematol Pathol 1991;5:83-8.
52. Barosi G, Liberate LN, Costa A, Buratti A, DiDio F, Salvatore S, et al. Induction and maintenance alpha-interferon therapy in myelofibrosis with myeloid metaplasia. Eur J Haematol 1990;45(Suppl 52):12-4.
53. Elliot MA, Tefferi A. Interferon-α therapy in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 1997;23:463-72.
54. Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981;304:441-7.